US 2022/0064623 A1 · ENDOLYSIN VARIANT

Abstract

The present invention relates to the field of antimicrobial enzymes. In particular, the present invention relates to a polypeptide comprising an amino acid sequence exhibiting at least 90% sequence identity with the sequence of SEQ ID NO:1, with the proviso that the polypeptide does neither comprise the sequence according to SEQ ID NO:2, nor the sequence according to SEQ ID NO:3, nor the sequence according to SEQ ID NO:4. The present invention relates also to nucleic acids encoding an inventive polypeptide, vectors or bacteriophages comprising an inventive nucleic acid as well as host cells comprising an inventive polypeptide, nucleic acid, vector, and/or bacteriophage. Similarly, the present invention relates to compositions comprising a polypeptide, nucleic acid, vector, bacteriophage, and/or host cell according to the present invention.

Claims14

Dependent claims

A nucleic acid encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:1, wherein SEQ ID NO:1 is characterized by:

X5 may be any amino acid,
X13 may be any amino acid,
X72 may be L or S,
X98 may be any amino acid;
with the proviso that the polypeptide does neither comprise the sequence according to SEQ ID NO:2, nor the sequence according to SEQ ID NO:3, nor the sequence according to SEQ ID NO:4.

2 more elements

Dependencies are inferred from the claim text.

Facts

Application

17/530,142Filed 18 Nov 2021

Priority

TH PCT/TH2016/00004827 May 2016

Published

3 Mar 2022

Term ends

Not estimatedThe source records don’t support an estimate.

Classification4 codes

C12N 9/80
Acting on carbon to nitrogen bonds other than peptide bonds: acting on amide bonds in linear amides
A61P 31/04
Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics: antibacterial agents
C12N
Microorganisms or enzymes
A61P
Therapeutic uses of medicines

Endolysin variant

Life of this patent

Endolysin variant

Life of this patent

Abstract

Claims14